Form 8-K   

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549  

FORM 8-K  

CURRENT REPORT  

Pursuant to Section 13 or 15(d)  

of the Securities Exchange Act of 1934  

Date of Report (Date of earliest event reported): January 13, 2015 (January 13, 2015)  

REGENERON PHARMACEUTICALS, INC.  

(Exact name of registrant as specified in its charter)  

New York  

(State or other jurisdiction  

of incorporation)  

  [DATA_TABLE_REMOVED] 

 777 Old Saw Mill River Road, Tarrytown, New York   10591-6707 

 (Address of principal executive offices)   (Zip Code)  

Registrant’s telephone number, including area code: (914) 847-7000  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):  

 ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

 ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

 ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

 Item 2.02. Results of Operations and Financial Condition.  

On January 13, 2015, at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., is providing a corporate update. Dr. Schleifer’s presentation includes on page 26 information regarding the Company’s preliminary U.S. net sales of EYLEA® (aflibercept) Injection for the full year 2014. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.  

The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.  

 Item 9.01. Financial Statements and Exhibits  

   (d) Exhibits.  

 99.1   Presentation by Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., at the 33rd Annual J.P. Morgan Healthcare Conference.  

SIGNATURES  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  

 REGENERON PHARMACEUTICALS, INC. 

/s/ Joseph J. LaRosa 

 Joseph J. LaRosa 

 Senior Vice President, General Counsel and Secretary  

Date: January 13, 2015  

EXHIBIT INDEX  

  [DATA_TABLE_REMOVED]